As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has approved ...
On a day when Vertex revealed trial data that indicate its next-generation cystic fibrosis (CF) treatment will soon be ready to grab the baton, the Boston company also presented (PDF) figures that ...
Investor's Business Daily on MSN
Why Vertex Pharma popped, as a key rival plummeted 92%
Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic ...
The last time I spoke about Vertex Pharmaceuticals (VRTX) it was with a Seeking Alpha article entitled "Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor ...
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
(RTTNews) - Vertex Pharmaceuticals (VRTX) announced Health Canada has granted Marketing Authorization for the expanded use of TRIKAFTA for the treatment of cystic fibrosis in patients aged 2 years and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results